-
Professor Dingwei Ye’s Team Showcases Surgical Expertise in Recurrent Prostate Cancer at the World Robotic Surgery Congress
From July 15 to 18, 2025, the annual global summit in the field of robotic surgery—the World Congress of the Society of Robotic Surgery (SRS)—was held in France, drawing together leading surgeons and pioneers in robotic technology from around the world. The event featured discussions on cutting-edge innovations and future trends, along with the presentation…
-
Vitamin C Shows Promise in Treating Advanced Kidney Cancer: Breakthrough Mechanism Identified by Research Teams Led by Professors Liqun Zhou, Xuesong Li, and Weimin Ci
Vitamin C, a vital nutrient known for its antioxidant, immune-boosting, and cosmetic benefits, has long been a subject of interest in cancer research. While its anti-tumor properties have been explored for years, the scientific community has remained divided, and the precise mechanisms by which Vitamin C may act against cancer—particularly metastatic renal cell carcinoma (RCC)—have…
-
EHA Expert Interview | Professor John Mascarenhas on INCA33989: A Breakthrough Monoclonal Antibody Therapy for Essential Thrombocythemia
Oncology Frontier – Hematology Frontier: Could you briefly explain the mechanism of action of INCA33989 in ET patients, and what the current study has shown in terms of safety and…
-
2025 Beijing Breast Cancer Forum | Prof. Que Zhang: Enhancing Early Screening in Primary Care, Upholding the Mission of Breast Oncology Advancement
The 2025 Beijing Breast Cancer Forum and Breast Reconstruction Symposium, held from June 25 to June 28 in Beijing, was hosted by the Beijing Society for Breast Disease Prevention and Treatment and co-organized by the Breast Center of Peking University People’s Hospital and the Jiaqing Breast Cancer Prevention Foundation. During the conference, Oncology Frontier invited…
-
ASCO Focus | Prof. Songqing Ye: New Strategies, New Breakthroughs — Interpreting the TRADE and OASIS-4 Study Results
At the 2025 ASCO Annual Meeting, two important studies—TRADE and OASIS-4—brought forward new treatment concepts and methods for early breast cancer, particularly in improving treatment adherence and patient quality of life. The TRADE study (Abstract No. 517) introduced a dose-escalation strategy for the CDK4/6 inhibitor abemaciclib in HR+/HER2− breast cancer patients, significantly improving adherence and…
-
ASCO Highlights | Prof. Jia Wang: New Five-Year Survival Evidence Supports Chemotherapy De-escalation in HER2-Positive Early Breast Cancer — Summary of Three WSG Trials Including ADAPT
At the 2025 ASCO Annual Meeting, the West German Study Group (WSG) presented a pooled analysis (Abstract No. 502) of three trials—including the ADAPT TP study—exploring survival outcomes following chemotherapy de-escalation in HER2-positive early breast cancer (eBC). Oncology Frontier invited Prof. Jia Wang and Dr. Jinze Yu from the Second Affiliated Hospital of Dalian Medical…
-
ASCO Highlights | Prof. Wenjin Yin: Who Benefits Most After CDK4/6i Failure? New Biomarker Insights from DESTINY-Breast06 Provide Clearer Answers
There is currently no universally accepted standard treatment for patients who progress after receiving CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i + ET). In the era of precision medicine, both domestic and international guidelines increasingly recommend biomarker-driven treatment strategies. However, the population covered by each biomarker is often limited, creating an urgent clinical need for…
-
Prof. Zefei Jiang Previews Highlights and Reflects on a Decade of Growth in Chinese Oncology
2025 BOC/BOA to Open on July 4th! From BOA to BOC/BOA: Chinese Scholars on the Global Stage Oncology Frontier: BOC/BOA 2025 is just around the corner. Over the years, you’ve…
Connecting Medical Expertise through Media